Business Wire

TX-PLANVIEW

1.5.2024 15:01:33 CEST | Business Wire | Press release

Share
Planview Accelerates Transformation Impact with Next Generation Connectivity, Visibility, and AI-Driven Insights

Planview, the leading end-to-end platform for Strategic Portfolio Management (SPM) and Digital Product Development (DPD), today announced a series of platform innovations designed to accelerate the speed and impact of transformation by connecting project and product initiative data across the enterprise. These innovations enable bi-directional visibility and governance to create tighter alignment between strategies and teams, harness AI to enhance predictability and strategic decision-making, and deliver personalized user experiences to uplevel productivity.

“Organizations today are struggling with data sprawl and misalignment across their disparate teams and tools, with negative impact to the speed and success of their transformation efforts,” said Louise K. Allen, Chief Product Officer. “The platform innovations released today change how the enterprise leverages and connects data, transitioning it from an unusable repository to an invaluable asset. We are breaking down data silos by connecting strategic priorities and the teams delivering the work, enabling organization-wide visibility to keep outcomes front and center.”

Accelerate Outcomes with Comprehensive Data Visibility and Personalization

Introducing Planview.Me™, an easy-to-use, personalized platform experience designed to bring data, insights, and work together into a single view. With Planview.Me, teams and individuals across roles and personas can:

  • Create configurable, unique views based on status, progress, stakeholder needs, and other data-oriented use cases.
  • Reduce platform clicks to surface the right information at the right time with clear actions in a single view, for an improved user experience.
  • Take action, investigate, respond, and react with a single click, increasing efficiency by having relevant data available at your fingertips.
  • Bring data and insight transparency into all decisions and to all decision-makers within the organization.

Uplevel Your Productivity with Actionable AI-Insights and Expert Guidance

Planview® Copilot is now available across Strategic Portfolio Management, Enterprise Agile Planning (EAP), Value Stream Management (VSM), and Digital Product Development solutions, including the Planview® Portfolios, Planview® Viz, Planview® AdaptiveWork, and Planview® AgilePlace products.

First introduced as an Early Access release in September 2023, Planview Copilot users can:

  • Converse with and question their data using natural language to glean insights, derive recommendations based on best practices, and inform strategic decisions.
  • Instantly tap into decades of Planview knowledge, best practices, and key learnings​.
  • Surface hidden insights and delivery risks across multiple initiatives, value streams, products, and projects​.
  • Increase productivity by analyzing and synthesizing vast amounts of data in seconds.

Further boosting Planview’s AI-enabled platform capabilities, Planview is strengthening its early-warning systems with additional sentiment analysis and aggregation across key products, including Planview Portfolios, Planview® AgilePlace, and Planview® ProjectPlace. Sentiment analysis can:

  • Create sentiment scores based on emotional tone across multiple comments and text entries to provide an overview of product, project, or work health.
  • Analyze trends over time to understand whether large bodies of work reflect positive, neutral, or negative sentiments.
  • Accurately reflect the status of the work outside of traditional red, amber, and green indicators.

“Connecting value stream data is a critical first step in creating the visibility needed to understand where your organizational challenges lie,” says Mik Kersten, Chief Technology Officer. “With Planview Copilot’s new skills and our robust early warning systems now embedded across the entire Planview Platform, we are empowering organizations with more than visibility – we are giving them the actionable insights that will shape their strategic decisions, drive productivity, and accelerate time to value for digital transformations.”

Redefine How Work Gets Done with Less Disruption and More Enterprise-wide Work Connectivity

With enhanced connectivity between Planview Portfolios and Planview ProjectPlace, Planview is bringing traditionally ungoverned work into the purview of portfolio leadership to ensure alignment, oversight, and governance while empowering teams to deliver projects with easy-to-use capabilities like Gantt, kanban, and document storage, in discrete workspaces with no manual status reporting. This enhancement drives greater team autonomy, allowing teams to continue working within their projects and programs without disruption, while providing leadership with the right level of visibility and oversight.

Finally, Planview introduces the Planview® Universal Connector, a strong addition to the 60+ software tool connectors it already has available. The Universal Connector enables organizations to automate and seamlessly integrate their third-party or homegrown software development tools directly into the Planview® Platform. By unlocking data siloed in disparate software delivery tools, data and work can flow directly into the Planview Platform, increasing data visibility and keeping productivity high without disrupting the native work and workflow processes of the delivery teams.

Additional Resources:

  • Learn more about the Planview Platform
  • Check out the Platform Demo to learn more about Planview.Me and Planview Copilot
  • Learn more about Planview Copilot
  • Register to attend Planview Accelerate on May 14-15, 2024, to learn more about Planview’s approach to Strategic Portfolio Management, Digital Product Development, Data, Generative AI, and Connected Work

About Planview

Planview is the leading end-to-end platform for Strategic Portfolio Management (SPM) and Digital Product Development (DPD), enabling organizations to plan and deliver large-scale digital transformation initiatives. Planview empowers organizations to improve time-to-market and predictability, increase efficiency to unlock capacity, and ensure their most strategic product and project initiatives deliver the desired business outcomes. Our connected platform of solutions underpins the business and digital transformations of more than 4,500 customers and 2.7 million users globally, including 59 of the Fortune 100. Headquartered in Austin, Texas, Planview has over 1,400 employees worldwide.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240429197434/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye